The Motley FoolSat, 11 Apr 2026 13:20:03 GMTBeam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.BEAM+3.49%
Zacks Investment ResearchThu, 26 Mar 2026 16:10:28 GMTBEAM Eyes Global Expansion of AATD Study After Strong Early DataBEAM+3.49%
Seeking AlphaThu, 26 Mar 2026 02:15:55 GMTBeam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency TranscriptBEAM+3.49%
BenzingaWed, 25 Mar 2026 14:31:56 GMTBeam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein LevelsBEAM+3.49%
Seeking AlphaFri, 27 Feb 2026 14:40:41 GMTBeam Therapeutics: Great Potential, But Patience Is NeededBEAM+3.49%
Zacks Investment ResearchWed, 25 Feb 2026 17:06:12 GMTBEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/YBEAM+3.49%
Seeking AlphaTue, 24 Feb 2026 21:57:55 GMTBeam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call TranscriptBEAM+3.49%
Zacks Investment ResearchTue, 24 Feb 2026 14:51:01 GMTBeam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue EstimatesBEAM+3.49%
The Motley FoolSun, 01 Feb 2026 08:46:01 GMTBeam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933BEAM+3.49%
